For research use only. Not for therapeutic Use.
JD-5037（Cat No.:I013696）is a small molecule inhibitor that targets the protein lysine-specific demethylase 1 (LSD1), an enzyme involved in epigenetic regulation. LSD1 is responsible for demethylating lysine residues on histones, which plays a key role in gene expression, cell differentiation, and cancer progression. By inhibiting LSD1, JD-5037 is being explored for its potential to treat various cancers, including leukemia, as well as other diseases involving aberrant gene expression. Preclinical studies have shown its ability to reduce tumor cell proliferation, but further research and clinical trials are needed to assess its safety, efficacy, and therapeutic potential.
| CAS Number | 1392116-14-1 |
| Molecular Formula | C₂₇H₂₇Cl₂N₅O₃S |
| Purity | ≥95% |
| Target | Cannabinoid Receptor |
| Solubility | DMSO: 10 mM |
| IUPAC Name | (2S)-2-[[[(4S)-5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-[(4-chlorophenyl)sulfonylamino]methylidene]amino]-3-methylbutanamide |
| InChI | InChI=1S/C27H27Cl2N5O3S/c1-17(2)24(26(30)35)31-27(33-38(36,37)22-14-12-21(29)13-15-22)34-16-23(18-6-4-3-5-7-18)25(32-34)19-8-10-20(28)11-9-19/h3-15,17,23-24H,16H2,1-2H3,(H2,30,35)(H,31,33)/t23-,24+/m1/s1 |
| InChIKey | GTCSIQFTNPTSLO-RPWUZVMVSA-N |
| SMILES | CC(C)[C@@H](C(=O)N)N=C(NS(=O)(=O)C1=CC=C(C=C1)Cl)N2C[C@@H](C(=N2)C3=CC=C(C=C3)Cl)C4=CC=CC=C4 |
| Reference | [1]. Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4751-60.<br>[2]. Knani I, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 2016 Oct 22;5(12):1187-1199.<br>[3]. Mukhopadhyay B, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology. 2015 May;61(5):1615-26. |
